Encountering the potentials of probiotics against urogenital tract infections in females

Year 2026, Volume: 30 Issue: 1, 246 - 262, 11.01.2026

Zainab Abdullah Khaleel Zahraa Amer Hashim , Vildan Celiksoy

https://doi.org/10.12991/jrespharm.1667840

Abstract

Urinary tract infection (UTI) and vaginitis are common conditions among females, significantly impacting overall life health and quality, imposing economical burdens and rising concerns of antibiotic resistance and limiting current treatments, probiotics have emerged as promising non antibiotic adjuvant and alternatives. Lactobacillus species restore and sustain a balanced microbiome offering protection against uro-pathogens by enhancement of epithelium barrier, immune modulation, competitive exclusions and biofilm disruptions. Clinical trials have documented the efficacy of probiotics both orally and vaginally in reducing UTI, preventing recurrences and restoring vaginal microbiota. This review highlights the aspects of probiotics mechanism of action, clinical trials and applications, exploring potentials of next generation probiotics and advancement in in delivery systems. While probiotics offer promising efficacy in managing UTI and vaginitis, further research studies are required to clarify exact mechanisms, strains potentials, dosage forms and doses, framing regulations regarding probiotics industry and tailored probiotics field.

Keywords

Probiotics , Urinary Tract , Females , Formulations , Infections

Ethical Statement

Not applicable

Supporting Institution

none

Project Number

Not applicable

References

• [1] Dason S, Dason JT, Kapoor A. Guidelines for thediagnosis and management of recurrent urinarytract infection in women. Can Urol Assoc J 2011;5: 316. https://doi.org/10.5489/cuaj.11214.
• [2] Foxman B. Epidemiology of urinary tract infections:incidence, morbidity, and economic costs. Am J Med. 2002;113(Suppl 1A):5S–13S. https://doi.org/10.1016/s0002-9343(02)01054-9.
• [3] Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014;28:1–13. https://doi.org/10.1016/j.idc.2013.09.003.
• [4] Al-Zidan RN, Mahmood SM, Younus ZM. The Antibiotic Susceptibility Patterns of Uro-pathogens among Adults with Recurrent Urinary Tract Infection in Mosul, Iraq. PHARMAKEFTIKI. 2024 36(II):77-88
• [5] Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269-84. https://doi.org/10.1038/nrmicro3432.
• [6] American College of Obstetricians and Gynecologists. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 76, October 2006: postpartum hemorrhage. Obstet Gynecol. 2006;108(4):1039-1047. https://doi.org/10.1097/00006250-200610000-00046.
• [7] Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):1-137. Erratum in: MMWR Recomm Rep. 2015;64(33):924.
• [8] Yano J, Sobel JD, Nyirjesy P, Sobel R, Williams VL, Yu Q, Noverr MC, Fidel PL Jr. Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes. BMC Womens Health. 2019;19(1):48. https://doi.org/10.1186/s12905-019-0748-8.
• [9] Foxman B, Barlow R, D'Arcy H, Gillespie B, Sobel JD. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol. 2000;10(8):509-515. https://doi.org/10.1016/s1047-2797(00)00072-7.
• [10] https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance.
• [11] Goebel MC, Trautner BW, Grigoryan L. The Five Ds of Outpatient Antibiotic Stewardship for Urinary Tract Infections. Clin Microbiol Rev. 2021;34(4):e0000320. https://doi.org/10.1128/cmr.00003-20.
• [12] Saraf VS, Sheikh SA, Ahmad A, Gillevet PM, Bokhari H, Javed S. Vaginal microbiome: normalcy vs dysbiosis. Arch Microbiol. 2021;203(7):3793-3802. https://doi.org/10.1007/s00203-021-02414-3.
• [13] Rauf A, Imran M, Abu-Izneid T, Iahtisham-Ul-Haq, Patel S, Pan X, Naz S, Sanches Silva A, Saeed F, Rasul Suleria HA. Proanthocyanidins: A comprehensive review. Biomed Pharmacother. 2019;116:108999. https://doi.org/10.1016/j.biopha.2019.108999.
• [14] Kranjčec B, Papeš D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014;32(1):79-84. https://doi.org/10.1007/s00345-013-1091-6.
• [15] Qasim ZS, Hashim ZA. Activity of Silybum marianum in Oral Candidiasis of Albino Rats. J Med Chem Sci. 2023; 6: 976-985.
• [16] Chen YY, Su TH, Lau HH. Estrogen for the prevention of recurrent urinary tract infections in postmenopausal women: a meta-analysis of randomized controlled trials. Int Urogynecol J. 2021;32(1):17-25. https://doi.org/10.1007/s00192-020-04397-z.
• [17] https://isappscience.org/
• [18] Hashim ZA. Evaluation of bacterial contents, package labelling and antimicrobial activity of some commercial probiotic products available in local market. J Res Pharm. 2022 ;26(3):502-509. http://dx.doi.org/10.29228/jrp.147.
• [19] Hashim ZA, Qasim ZS. Assessment of Saccharomyces boulardii effect on rats Staphylococcus aureus induced skin infection: an in-vivo study. J Res Pharm. 2022 ;26(5): 1342-1351. http://dx.doi.org/10.29228/jrp.226.
• [20] Maftei NM, Raileanu CR, Balta AA, Ambrose L, Boev M, Marin DB, Lisa EL. The potential impact of probiotics on human health: An update on their health-promoting properties. Microorganisms. 2024 ;12(2):234. https://doi.org/10.3390/microorganisms12020234.
• [21] Suzumura EA, Bersch-Ferreira ÂC, Torreglosa CR, da Silva JT, Coqueiro AY, Kuntz MGF, Chrispim PP, Weber B, Cavalcanti AB. Effects of oral supplementation with probiotics or synbiotics in overweight and obese adults: a systematic review and meta-analyses of randomized trials. Nutr Rev. 2019 ;77(6):430-450. https://doi.org/10.1093/nutrit/nuz001.
• [22] Xiang S, Ji JL, Li S, Cao XP, Xu W, Tan L, Tan CC. Efficacy and safety of probiotics for the treatment of Alzheimer's disease, mild cognitive impairment, and Parkinson's disease: a systematic review and meta-analysis. Front Aging Neurosci. 2022;14:730036. https://doi.org/10.3389/fnagi.2022.730036.
• [23] Akhgarjand C, Vahabi Z, Shab-Bidar S, Etesam F, Djafarian K. Effects of probiotic supplements on cognition, anxiety, and physical activity in subjects with mild and moderate Alzheimer’s disease: A randomized, double-blind, and placebo-controlled study. Front Aging Neurosci. 2022;14:1032494. https://doi.org/10.3389/fnagi.2022.1032494.
• [24] Bungau SG, Behl T, Singh A, Sehgal A, Singh S, Chigurupati S, Vijayabalan S, Das S, Palanimuthu VR. Targeting probiotics in rheumatoid arthritis. Nutrients. 2021;13(10):3376. https://doi.org/10.3390/nu13103376.
• [25] Aldabbagh KA, Hashim ZA, Qasim ZS. TAS2R38 gene in relation to Helicobacter pylori infection and blood groups in different age groups. Pharmacia. 2023;70:197-202. https://doi.org/10.3897/pharmacia.70.e97329.
• [26] https://openknowledge.fao.org/server/api/core/bitstreams/382476b3-4d54-4175-803f-2f26f3526256/content
• [27] NIH HMP Working Group; Peterson J, Garges S, Giovanni M, McInnes P, Wang L, Schloss JA, Bonazzi V, McEwen JE, Wetterstrand KA, Deal C, Baker CC, Di Francesco V, Howcroft TK, Karp RW, Lunsford RD, Wellington CR, Belachew T, Wright M, Giblin C, David H, Mills M, Salomon R, Mullins C, Akolkar B, Begg L, Davis C, Grandison L, Humble M, Khalsa J, Little AR, Peavy H, Pontzer C, Portnoy M, Sayre MH, Starke-Reed P, Zakhari S, Read J, Watson B, Guyer M. The NIH Human Microbiome Project. Genome Res. 2009;19(12):2317-2323. https://doi.org/10.1101/gr.096651.109.
• [28] Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014;11:506-514. https://doi.org/10.1038/nrgastro.2014.66.
• [29] https://ods.od.nih.gov/factsheets/Probiotics-HealthProfessiona
• [30] Jankovic I, Sybesma W, Phothirath P, Ananta E, Mercenier A. Application of probiotics in food products--challenges and new approaches. Curr Opin Biotechnol. 2010;21(2):175-181. https://doi.org/10.1016/j.copbio.2010.03.009.
• [31] Kesen MA, Aiyegoro OA. Beneficial characteristics and evaluation criteria of probiotics. Int J Food Biosci. 2018;1(1):19-26.
• [32] Vasiljevic T, Shah NP. Probiotics-from Metchnikoff to bioactive. Int Dairy J. 2008; 18: 714-728. https://doi.org/10.1016/j.idairyj.2008.03.004.
• [33] Hyronimus B, Le Marrec C, Sassi AH, Deschamps A. Acid and bile tolerance of spore-forming lactic acid bacteria. Int J Food Microbiol. 2000;61(2-3):193-177. https://doi.org/10.1016/s0168-1605(00)00366-4.
• [34] Mureşan A, Sârbu I, Pelinescu D, Ionescu R, Csutak O, Stoica I, Vassu-Dimov T. In vitro selection of some lactic acid bacteria strains with probiotic potential. Romanian Biotechnol Lett. 2018;23(1):13327.
• [35] Hashim ZA, Maillard JY, Wilson MJ, Waddington RJ. Determining the potential use of biosurfactants in preventing endodontic infections. Eur J Oral Sci. 2022;130(6):e12900. https://doi.org/10.1111/eos.12900.
• [36] Wei YX, Zhang ZY, Liu C, Malakar PK, Guo XK. Safety assessment of Bifidobacterium longum JDM301 based on complete genome sequences. World J Gastroenterol. 2012;18(5):479-488. https://doi.org/10.3748/wjg.v18.i5.479.
• [37] Dlamini ZC, Langa RLS, Aiyegoro OA, Okoh AI. Safety Evaluation and Colonisation Abilities of Four Lactic Acid Bacteria as Future Probiotics. Probiotics Antimicrob Proteins. 2019;11(2):397-402. https://doi.org/10.1007/s12602-018-9430-y.
• [38] Spyropoulos BG, Misiakos EP, Fotiadis C, Stoidis CN. Antioxidant properties of probiotics and their protective effects in the pathogenesis of radiation-induced enteritis and colitis. Dig Dis Sci. 2011;56(2):285-294. https://doi.org/10.1007/s10620-010-1307-1.
• [39] Gómez NC, Ramiro JM, Quecan BX, de Melo Franco BD. Use of potential probiotic lactic acid bacteria (LAB) biofilms for the control of Listeria monocytogenes, Salmonella Typhimurium, and Escherichia coli O157: H7 biofilms formation. Front Microbiol. 2016;7:863. https://doi.org/10.3389/fmicb.2016.00863.
• [40] Janković T, Frece J, Abram M, Gobin I. Aggregation ability of potential probiotic Lactobacillus plantarum strains. Int J Sanitary Eng Res. 2012;6(1):19-24.
• [41] Shuker DE. The enemy at the gates? DNA adducts as biomarkers of exposure to exogenous and endogenous genotoxic agents. Toxicol Lett. 2002;134(1-3):51-56. https://doi.org/10.1016/s0378-4274(02)00162-5.
• [42] Anadón A, Martínez-Larrañaga MR, Ares I, Martínez MA. Probiotics: safety and toxicity considerations. In: Nutraceuticals 2016 ; pp. 777-798. Academic Press.
• [43] Kechagia M, Basoulis D, Konstantopoulou S, Dimitriadi D, Gyftopoulou K, Skarmoutsou N, Fakiri EM. Health benefits of probiotics: a review. ISRN Nutr. 2013;2013:481651. https://doi.org/10.5402/2013/481651.
• [44] Saarela M, Mogensen G, Fonden R, Mättö J, Mattila-Sandholm T. Probiotic bacteria: safety, functional and technological properties. J Biotechnol. 2000;84(3):197-215. https://doi.org/10.1016/s0168-1656(00)00375-8.
• [45] Gogineni VK, Morrow LE, Malesker MA. Probiotics: mechanisms of action and clinical applications. J Prob Health. 2013;1(101):2.
• [46] Latif A, Shehzad A, Niazi S, Zahid A, Ashraf W, Iqbal MW, Rehman A, Riaz T, Aadil RM, Khan IM, Özogul F. Probiotics: Mechanism of action, health benefits and their application in food industries. Front Microbiol. 2023;14:1216674. https://doi.org/10.3389/fmicb.2023.1216674.
• [47] Bermudez-Brito M, Plaza-Díaz J, Muñoz-Quezada S, Gómez-Llorente C, Gil A. Probiotic mechanisms of action. Ann Nutr Metab. 2012;61(2):160-174. https://doi.org/10.1159/000342079.
• [48] Bu Y, Liu Y, Liu Y, Wang S, Liu Q, Hao H, Yi H. Screening and probiotic potential evaluation of bacteriocin-producing Lactiplantibacillus plantarum in vitro. Foods. 2022;11(11):1575. https://doi.org/10.3390/foods11111575.
• [49] Gaudier E, Michel C, Segain JP, Cherbut C, Hoebler C. The VSL# 3 probiotic mixture modifies microflora but does not heal chronic dextran-sodium sulfate–induced colitis or reinforce the mucus barrier in mice. J Nutr. 2005;135(12):2753-2761. https://doi.org/10.1093/jn/135.12.2753.
• [50] Chang YH, Jeong CH, Cheng WN, Choi Y, Shin DM, Lee S, Han SG. Quality characteristics of yogurts fermented with short-chain fatty acid-producing probiotics and their effects on mucin production and probiotic adhesion onto human colon epithelial cells. J Dairy Sci. 2021;104(7):7415-7425. https://doi.org/10.3168/jds.2020-19820.
• [51] Yousefi B, Eslami M, Ghasemian A, Kokhaei P, Salek Farrokhi A, Darabi N. Probiotics importance and their immunomodulatory properties. J Cell Physiol. 2019;234(6):8008-8018. https://doi.org/10.1002/jcp.27559.
• [52] Asahara T, Shimizu K, Takada T, Kado S, Yuki N, Morotomi M, Tanaka R, Nomoto K. Protective effect of Lactobacillus casei strain Shirota against lethal infection with multi‐drug resistant Salmonella enterica serovar Typhimurium DT104 in mice. J Appl Microbiol. 2011;110(1):163-173. https://doi.org/10.1111/j.1365-2672.2010.04884.x.
• [53] Vinderola G, Matar C, Perdigon G. Role of intestinal epithelial cells in immune effects mediated by gram-positive probiotic bacteria: involvement of toll-like receptors. Clin Diagn Lab Immunol. 2005;12(9):1075-1084. https://doi.org/10.1128/cdli.12.9.1075-1084.2005.
• [54] Petruzziello C, Saviano A, Ojetti V. Probiotics, the immune response and acute appendicitis: a review. Vaccines (Basel). 2023;11(7):1170. https://doi.org/10.3390/vaccines11071170.
• [55] Wu X, Vallance BA, Boyer L, Bergstrom KS, Walker J, Madsen K, O'Kusky JR, Buchan AM, Jacobson K. Saccharomyces boulardii ameliorates Citrobacter rodentium-induced colitis through actions on bacterial virulence factors. Am J Physiol Gastrointest Liver Physiol. 2008;294(1):G295-306. https://doi.org/10.1152/ajpgi.00173.2007.
• [56] Schiffrin EJ, Blum S. Interactions between the microbiota and the intestinal mucosa. Eur J Clin Nutr. 2002;56 Suppl 3:S60-64. https://doi.org/10.1038/sj.ejcn.1601489.
• [57] O'Shea EF, Cotter PD, Stanton C, Ross RP, Hill C. Production of bioactive substances by intestinal bacteria as a basis for explaining probiotic mechanisms: bacteriocins and conjugated linoleic acid. Int J Food Microbiol. 2012;152(3):189-205. https://doi.org/10.1016/j.ijfoodmicro.2011.05.025.
• [58] Ahire JJ, Jakkamsetty C, Kashikar MS, Lakshmi SG, Madempudi RS. In vitro evaluation of probiotic properties of Lactobacillus plantarum UBLP40 isolated from traditional indigenous fermented food. Probiotics Antimicrob Proteins. 2021; 13(5):1413-1424. https://doi.org/10.1007/s12602-021-09775-7.
• [59] Ahire JJ, Mokashe NU, Patil HJ, Chaudhari BL. Antioxidative potential of folate producing probiotic Lactobacillus helveticus CD6. J Food Sci Technol. 2013;50(1):26-34. https://doi.org/10.1007/s13197-011-0244-0.
• [60] Bjarnsholt T, Buhlin K, Dufrêne YF, Gomelsky M, Moroni A, Ramstedt M, Rumbaugh KP, Schulte T, Sun L, Åkerlund B, Römling U. Biofilm formation–what we can learn from recent developments. J Intern Med. 2018;284(4):332-345. https://doi.org/10.1111/joim.12782.
• [61] Ceresa C, Rinaldi M, Tessarolo F, Maniglio D, Fedeli E, Tambone E, Caciagli P, Banat IM, Diaz De Rienzo MA, Fracchia L. Inhibitory effects of lipopeptides and glycolipids on C. albicans–Staphylococcus spp. dual-species biofilms. Front Microbiol. 2021;11:545654. https://doi.org/10.3389/fmicb.2020.545654.
• [62] Onbas T, Osmanagaoglu O, Kiran F. Potential properties of Lactobacillus plantarum F-10 as a bio-control strategy for wound infections. Probiotics Antimicrob Proteins. 2019;11(4):1110-1123. https://doi.org/10.1007/s12602-018-9486-8.
• [63] Barzegari A, Kheyrolahzadeh K, Hosseiniyan Khatibi SM, Sharifi S, Memar MY, Zununi Vahed S. The battle of probiotics and their derivatives against biofilms. Infect Drug Resist. 2020;13:659-672. https://doi.org/10.2147/idr.s232982.
• [64] Medellin-Pena MJ, Wang H, Johnson R, Anand S, Griffiths MW. Probiotics affect virulence-related gene expression in Escherichia coli O157: H7. Appl Environ Microbiol. 2007;73(13):4259-4267. https://doi.org/10.1128/aem.00159-07.
• [65] Leendertz SA, Locatelli S, Boesch C, Kücherer C, Formenty P, Liegeois F, Ayouba A, Peeters M, Leendertz FH. No evidence for transmission of SIVwrc from western red colobus monkeys (Piliocolobus badius badius) to wild West African chimpanzees (Pan troglodytes verus) despite high exposure through hunting. BMC Microbiol. 2011;11(1):24. https://doi.org/10.1186/1471-2180-11-24.
• [66] Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet. 2012 ;13(4):260-270. https://doi.org/10.1038/nrg3182.
• [67] Pearce MM, Hilt EE, Rosenfeld AB, Zilliox MJ, Thomas-White K, Fok C, Kliethermes S, Schreckenberger PC, Brubaker L, Gai X, Wolfe AJ. The female urinary microbiome: a comparison of women with and without urgency urinary incontinence. mBio. 2014;5(4):e01283-14. https://doi.org/10.1128/mbio.01283-14.
• [68] Bolton M, Van Der Straten A, Cohen CR. Probiotics: potential to prevent HIV and sexually transmitted infections in women. Sex Transm Dis. 2008;35(3):214-225. https://doi.org/10.1097/olq.0b013e31815b017a.
• [69] Lewis AL, Gilbert NM. Roles of the vagina and the vaginal microbiota in urinary tract infection: evidence from clinical correlations and experimental models. GMS Infect Dis. 2020;8:Doc02. https://doi.org/10.3205/id000046.
• [70] Sadeghi-Bojd S, Naghshizadian R, Mazaheri M, Ghane Sharbaf F, Assadi F. Efficacy of probiotic prophylaxis after the first febrile urinary tract infection in children with normal urinary tracts. J Pediatric Infect Dis Soc. 2020 ;9(3):305-310. https://doi.org/10.1093/jpids/piz025.
• [71] Assafi MS, Ali FF, Polis RF, Sabaly NJ, Qarani SM. An epidemiological and multidrug resistance study for E. coli isolated from urinary tract infection (three years of study). Baghdad Sci J. 2022;19(1):0007.
• [72] Simoni A, Schwartz L, Junquera GY, Ching CB, Spencer JD. Current and emerging strategies to curb antibiotic-resistant urinary tract infections. Nat Rev Urol. 2024;21(12):707-722. https://doi.org/10.1038/s41585-024-00877-9.
• [73] Tien MT, Girardin SE, Regnault B, Le Bourhis L, Dillies MA, Coppée JY, Bourdet-Sicard R, Sansonetti PJ, Pédron T. Anti-inflammatory effect of Lactobacillus casei on Shigella-infected human intestinal epithelial cells. J Immunol. 2006;176(2):1228-37. doi: 10.4049/jimmunol.176.2.1228. Erratum in: J Immunol. 2006;176(6):3841. https://doi.org/10.4049/jimmunol.176.2.1228.
• [74] Gupta V, Mastromarino P, Garg R. Effectiveness of prophylactic oral and/or vaginal probiotic supplementation in the prevention of recurrent urinary tract infections: A randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2024;78(5):1154-1161. https://doi.org/10.1093/cid/ciad766.
• [75] Abdullatif VA, Sur RL, Eshaghian E, Gaura KA, Goldman B, Panchatsharam PK, Williams NJ, Abbott JE. Efficacy of probiotics as prophylaxis for urinary tract infections in premenopausal women: a systematic review and meta-analysis. Cureus. 2021;13(10):e18843. https://doi.org/10.7759/cureus.18843.
• [76] Akgül T, Karakan T. The role of probiotics in women with recurrent urinary tract infections. Turk J Urol. 2018;44(5):377-383. https://doi.org/10.5152/tud.2018.48742.
• [77] Grin PM, Kowalewska PM, Alhazzan W, Fox-Robichaud AE. Lactobacillus for preventing recurrent urinary tract infections in women: meta-analysis. Can J Urol. 2013 Feb 1;20(1):6607-6614.
• [78] Reid G, Bruce AW, Taylor M. Influence of three-day antimicrobial therapy and lactobacillus vaginal suppositories on recurrence of urinary tract infections. Clin Ther. 1992;14(1):11-16.
• [79] Reid G. Instillation of Lactobacillus and stimulation of indigenous organisms to prevent recurrence of urinary tract infections. Infect Immun. 1985;49(2):320-324. https://doi.org/10.1128/iai.49.2.320-324.1985.
• [80] Stapleton AE, Au-Yeung M, Hooton TM, Fredricks DN, Roberts PL, Czaja CA, Yarova-Yarovaya Y, Fiedler T, Cox M, Stamm WE. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis. 2011;52(10):1212-1217. https://doi.org/10.1093/cid/cir183.
• [81] Beerepoot MA, ter Riet G, Nys S, van der Wal WM, de Borgie CA, de Reijke TM, Prins JM, Koeijers J, Verbon A, Stobberingh E, Geerlings SE. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women. Arch Intern Med. 2012;172(9):704-712. https://doi.org/10.1001/archinternmed.2012.777.
• [82] Montorsi F, Gandaglia G, Salonia A, Briganti A, Mirone V. Effectiveness of a combination of cranberries, Lactobacillus rhamnosus, and vitamin C for the management of recurrent urinary tract infections in women: results of a pilot study.Eur Urol. 2016;70(6):912-915. https://doi.org/10.1016/j.eururo.2016.05.042.
• [83] Coudray MS, Madhivanan P. Bacterial vaginosis—A brief synopsis of the literature. Eur J Obstet Gynecol Reprod Biol. 2020;245:143-148. https://doi.org/10.1016/j.ejogrb.2019.12.035.
• [84] Schwebke JR, Muzny CA, Josey WE. Role of Gardnerella vaginalis in the pathogenesis of bacterial vaginosis: a conceptual model. J Infect Dis. 2014;210(3):338-343. https://doi.org/10.1093/infdis/jiu089.
• [85] Bradshaw CS, Vodstrcil LA, Hocking JS, Law M, Pirotta M, Garland SM, De Guingand D, Morton AN, Fairley CK. Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use. Clin Infect Dis. 2013;56(6):777-786. https://doi.org/10.1093/cid/cis1030.
• [86] Smith SB, Ravel J. The vaginal microbiota, host defence and reproductive physiology. J Physiol. 2017 ;595(2):451-463. https://doi.org/10.1113/jp271694.
• [87] Ravel J, Moreno I, Simón C. Bacterial vaginosis and its association with infertility, endometritis, and pelvic inflammatory disease. Am J Obstet Gynecol. 2021;224(3):251-257. https://doi.org/10.1016/j.ajog.2020.10.019.
• [88] Aslam B, Khurshid M, Arshad MI, Muzammil S, Rasool M, Yasmeen N, Shah T, Chaudhry TH, Rasool MH, Shahid A, Xueshan X. Antibiotic resistance: one health one world outlook. Front Cell Infect Microbiol. 2021;11:771510. https://doi.org/10.3389/fcimb.2021.771510.
• [89] Menichini D, Chiossi G, Monari F, De Seta F, Facchinetti F. Supplementation of probiotics in pregnant women targeting group b streptococcus colonization: A systematic review and meta-analysis. Nutrients. 2022;14(21):4520. https://doi.org/10.3390/nu14214520.
• [90] Zawistowska-Rojek A, Kośmider A, Stępień K, Tyski S. Adhesion and aggregation properties of Lactobacillaceae strains as protection ways against enteropathogenic bacteria. Arch Microbiol. 2022 ;204(5):285. https://doi.org/10.1007/s00203-022-02889-8.
• [91] France M, Alizadeh M, Brown S, Ma B, Ravel J. Towards a deeper understanding of the vaginal microbiota. Nat Microbiol. 2022;7(3):367-378. https://doi.org/10.1038/s41564-022-01083-2.
• [92] Bonneville L, Maia V, Barroso I, Martínez-Suárez JV, Brito L. Lactobacillus plantarum in dual-species biofilms with Listeria monocytogenes enhanced the anti-Listeria activity of a commercial disinfectant based on hydrogen peroxide and peracetic acid. Front Microbiol. 2021;12:631627. https://doi.org/10.3389/fmicb.2021.631627.
• [93] Darbandi A, Asadi A, Mahdizade Ari M, Ohadi E, Talebi M, Halaj Zadeh M, Darb Emamie A, Ghanavati R, Kakanj M. Bacteriocins: properties and potential use as antimicrobials. J Clin Lab Anal. 2022;36(1):e24093. https://doi.org/10.1002/jcla.24093.
• [94] Patel M, Siddiqui AJ, Hamadou WS, Surti M, Awadelkareem AM, Ashraf SA, Alreshidi M, Snoussi M, Rizvi SM, Bardakci F, Jamal A. Inhibition of bacterial adhesion and antibiofilm activities of a glycolipid biosurfactant from Lactobacillus rhamnosus with its physicochemical and functional properties. Antibiotics. 2021 ;10(12):1546. https://doi.org/10.3390/antibiotics10121546.
• [95] Koirala R, Gargari G, Arioli S, Taverniti V, Fiore W, Grossi E, Anelli GM, Cetin I, Guglielmetti S. Effect of oral consumption of capsules containing Lactobacillus paracasei LPC-S01 on the vaginal microbiota of healthy adult women: a randomized, placebo-controlled, double-blind crossover study. FEMS Microbiol Ecol. 2020;96(6):fiaa084. https://doi.org/10.1093/femsec/fiaa084.
• [96] Mitchell CM, Ma N, Mitchell AJ, Wu MC, Valint DJ, Proll S, Reed SD, Guthrie KA, Lacroix AZ, Larson JC, Pepin R. Association between postmenopausal vulvovaginal discomfort, vaginal microbiota, and mucosal inflammation. Am J Obstet Gynecol. 2021;225(2):159.e1-159.e15. https://doi.org/10.1016/j.ajog.2021.02.034.
• [97] Mastromarino P, Macchia S, Meggiorini L, Trinchieri V, Mosca L, Perluigi M, Midulla C. Effectiveness of Lactobacillus-containing vaginal tablets in the treatment of symptomatic bacterial vaginosis. Clin Microbiol Infect. 2009;15(1):67-74. https://doi.org/10.1111/j.1469-0691.2008.02112.x.
• [98] Hemalatha R, Mastromarino P, Ramalaxmi BA, Balakrishna NV, Sesikeran B. Effectiveness of vaginal tablets containing lactobacilli versus pH tablets on vaginal health and inflammatory cytokines: a randomized, double-blind study. Eur J Clin Microbiol Infect Dis. 2012;31(11):3097-3105. https://doi.org/10.1007/s10096-012-1671-1.
• [99] Vujic G, Knez AJ, Stefanovic VD, Vrbanovic VK. Efficacy of orally applied probiotic capsules for bacterial vaginosis and other vaginal infections: a double-blind, randomized, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol. 2013;168(1):75-79. https://doi.org/10.1016/j.ejogrb.2012.12.031.
• [100] Vicariotto F, Mogna L, Del Piano M. Effectiveness of the two microorganisms Lactobacillus fermentum LF15 and Lactobacillus plantarum LP01, formulated in slow-release vaginal tablets, in women affected by bacterial vaginosis: a pilot study. J Clin Gastroenterol. 2014;48 Suppl 1:S106-112. https://doi.org/10.1097/mcg.0000000000000226.
• [101] Murina F, Graziottin A, Vicariotto F, De Seta F. Can Lactobacillus fermentum LF10 and Lactobacillus acidophilus LA02 in a slow-release vaginal product be useful for prevention of recurrent vulvovaginal candidiasis?: a clinical study. J Clin Gastroenterol. 2014;48 Suppl 1:S102-105. https://doi.org/10.1097/mcg.0000000000000225.
• [102] Vicariotto F, Del Piano M, Mogna L, Mogna G. Effectiveness of the association of 2 probiotic strains formulated in a slow release vaginal product, in women affected by vulvovaginal candidiasis: a pilot study. J Clin Gastroenterol. 2012;46 Suppl:S73-80. https://doi.org/10.1097/mcg.0b013e3182684d71.
• [103] Mulak A, Bonaz B. Brain-gut-microbiota axis in Parkinson's disease. World J Gastroenterol. 2015;21(37):10609-10620. https://doi.org/10.3748/wjg.v21.i37.10609.
• [104] Hoel H, Heggelund L, Reikvam DH, Stiksrud B, Ueland T, Michelsen AE, Otterdal K, Muller KE, Lind A, Muller F, Dudman S. Elevated markers of gut leakage and inflammasome activation in COVID‐19 patients with cardiac involvement. J Intern Med. 2021;289(4):523-531. https://doi.org/10.1111/joim.13178.
• [105] Hardy H, Harris J, Lyon E, Beal J, Foey AD. Probiotics, prebiotics and immunomodulation of gut mucosal defences: homeostasis and immunopathology. Nutrients. 2013;5(6):1869-1912. https://doi.org/10.3390/nu5061869.
• [106] Koradia P, Kapadia S, Trivedi Y, Chanchu G, Harper A. Probiotic and cranberry supplementation for preventing recurrent uncomplicated urinary tract infections in premenopausal women: a controlled pilot study. Expert Rev Anti Infect Ther. 2019 ;17(9):733-740. https://doi.org/10.1080/14787210.2019.1664287.
• [107] Homayouni A, Bastani P, Ziyadi S, Mohammad-Alizadeh-Charandabi S, Ghalibaf M, Mortazavian AM, Mehrabany EV. Effects of probiotics on the recurrence of bacterial vaginosis: a review. J Low Genit Tract Dis. 2014;18(1):79-86. https://doi.org/10.1097/lgt.0b013e31829156ec.
• [108] Ng QX, Peters C, Venkatanarayanan N, Goh YY, Ho CY, Yeo WS. Use of Lactobacillus spp. to prevent recurrent urinary tract infections in females. Med Hypotheses. 2018;114:49-54. https://doi.org/10.1016/j.mehy.2018.03.001.
• [109] Markovic S, Suman VJ, Dalton RJ, Woods JE, Fitzgibbons Jr RJ, Wold LE, Buckner JC, Kugler JW, Mailliard JA, Rowland KM, Krook JE. Randomized, placebo-controlled, phase III surgical adjuvant clinical trial of megestrol acetate (Megace) in selected patients with malignant melanoma. Am J Clin Oncol. 2002;25(6):552-556. https://doi.org/10.1097/00000421-200212000-00003.
• [110] Ozkinay E, Terek MC, Yayci M, Kaiser R, Grob P, Tuncay G. The effectiveness of live lactobacilli in combination with low dose oestriol (Gynoflor) to restore the vaginal flora after treatment of vaginal infections. BJOG. 2005;112(2):234-240. https://doi.org/10.1111/j.1471-0528.2004.00329.x.
• [111] Ehrström S, Daroczy K, Rylander E, Samuelsson C, Johannesson U, Anzén B, Påhlson C. Lactic acid bacteria colonization and clinical outcome after probiotic supplementation in conventionally treated bacterial vaginosis and vulvovaginal candidiasis. Microbes Infect. 2010 ;12(10):691-699. https://doi.org/10.1016/j.micinf.2010.04.010.
• [112] Sikorska H, Smoragiewicz W. Role of probiotics in the prevention and treatment of meticillin-resistant Staphylococcus aureus infections. Int J Antimicrob Agents. 2013;42(6):475-481. https://doi.org/10.1016/j.ijantimicag.2013.08.003.
• [113] Gao Y, Lu Y, Teng KL, Chen ML, Zheng HJ, Zhu YQ, Zhong J. Complete genome sequence of Lactococcus lactis subsp. lactis CV56, a probiotic strain isolated from the vaginas of healthy women. J Bacteriol. 2011;193(11):2886-2887. https://doi.org/10.1128/jb.00358-11.
• [114] Mastromarino P, Macchia S, Meggiorini L, Trinchieri V, Mosca L, Perluigi M, Midulla C. Effectiveness of Lactobacillus-containing vaginal tablets in the treatment of symptomatic bacterial vaginosis. Clin Microbiol Infect. 2009;15(1):67-74. https://doi.org/10.1111/j.1469-0691.2008.02112.x.
• [115] Benmechernene Z, Chentouf HF, Yahia B, Fatima G, Quintela-Baluja M, Calo-Mata P, Barros-Velázquez J. Technological aptitude and applications of Leuconostoc mesenteroides bioactive strains isolated from Algerian raw camel milk. Biomed Res Int. 2013;2013:418132. https://doi.org/10.1155/2013/418132.
• [116] Gaziano R, Sabbatini S, Roselletti E, Perito S, Monari C. Saccharomyces cerevisiae-based probiotics as novel antimicrobial agents to prevent and treat vaginal infections. Front Microbiol. 2020;11:718. Front Microbiol. 2020;11:718. https://doi.org/10.3389/fmicb.2020.00718.
• [117] Veiga P, Suez J, Derrien M, Elinav E. Moving from probiotics to precision probiotics. Nat Microbiol. 2020;5(7):878-880. https://doi.org/10.1038/s41564-020-0721-1.
• [118] Barzegari A, Saei AA. Designing probiotics with respect to the native microbiome. Future Microbiol. 2012;7(5):571-575. https://doi.org/10.2217/fmb.12.37.
• [119] Roobab U, Batool Z, Manzoor MF, Shabbir MA, Khan MR, Aadil RM. Sources, formulations, advanced delivery and health benefits of probiotics. Curr Opin Food Sci. 2020;32:17-28. https://doi.org/10.1016/j.cofs.2020.01.003.
• [120] Yao M, Xie J, Du H, McClements DJ, Xiao H, Li L. Progress in microencapsulation of probiotics: A review. Comprehens Rev Food Sci Food Saf. 2020;19(2):857-874. https://doi.org/10.1111/1541-4337.12532.
• [121] Kim J, Muhammad N, Jhun BH, Yoo JW. Probiotic delivery systems: A brief overview. J Pharm Investig. 2016;46:377-386. https://doi.org/10.1007/s40005-016-0259-7.
• [122] Hashim ZA, Celiksoy V. Pharmaceutical products microbial contamination; approaches of detection and avoidance. Microb Infect Dis. 2025;6(1):159-170. https://doi.org/10.21608/mid.2024.266636.1785.
• [123] Baral KC, Bajracharya R, Lee SH, Han HK. Advancements in the pharmaceutical applications of probiotics: Dosage forms and formulation technology. Int J Nanomedicine. 2021; 7535-7556. https://doi.org/10.2147/ijn.s337427.
• [124] Dodoo CC, Wang J, Basit AW, Stapleton P, Gaisford S. Targeted delivery of probiotics to enhance gastrointestinal stability and intestinal colonisation. Int J Pharm. 2017;530(1-2):224-229. https://doi.org/10.1016/j.ijpharm.2017.07.068.
• [125] Kim WS, Cho CS, Hong L, Han GG, Kil BJ, Kang SK, Kim DD, Choi YJ, Huh CS. Oral delivery of probiotics using pH-sensitive phthalyl inulin tablets. J Microbiol Biotechnol. 2019;29(2):200-208. https://doi.org/10.4014/jmb.1811.11021.
• [126] Her JY, Kim MS, Lee KG. Preparation of probiotic powder by the spray freeze-drying method. J Food Eng. 2015;150:70-74.
• [127] Rodrigues F, Maia MJ, das Neves J, Sarmento B, Amaral MH, PP Oliveira MB. Vaginal suppositories containing Lactobacillus acidophilus: development and characterization. Drug Dev Ind Pharm. 2015;41(9):1518-1525. https://doi.org/10.3109/03639045.2014.963864.
• [128] Sánchez MT, Ruiz MA, Castán H, Morales ME. A novel double-layer mucoadhesive tablet containing probiotic strain for vaginal administration: Design, development and technological evaluation. Eur J Pharm Sci. 2018;112:63-70. https://doi.org/10.1016/j.ejps.2017.11.006.
• [129] Vigani B, Faccendini A, Rossi S, Sandri G, Bonferoni MC, Grisoli P, Ferrari F. Development of a mucoadhesive in situ gelling formulation for the delivery of Lactobacillus gasseri into vaginal cavity. Pharmaceutics. 2019;11(10):511. https://doi.org/10.3390/pharmaceutics11100511.
• [130] Ghibaudo F, Gerbino E, Copello GJ, Campo Dall' Orto V, Gómez-Zavaglia A. Pectin-decorated magnetite nanoparticles as both iron delivery systems and protective matrices for probiotic bacteria. Colloids Surf B Biointerfaces. ;180:193-201. https://doi.org/10.1016/j.colsurfb.2019.04.049.
• [131] Silva JA, De Gregorio PR, Rivero G, Abraham GA, Nader-Macías MEF. Immobilization of vaginal Lactobacillus in polymeric nanofibers for its incorporation in vaginal probiotic products. Eur J Pharm Sci. 2021;156:105563. https://doi.org/10.1016/j.ejps.2020.105563.
• [132] Savoia C, Volpe M, Grassi G, Borghi C, Agabiti Rosei E, Touyz RM. Personalized medicine-a modern approach for the diagnosis and management of hypertension. Clin Sci (Lond). 2017;131(22):2671-2685. https://doi.org/10.1042/cs20160407.
• [133] Cai L, Li Q, Deng Y, Liu X, Du W, Jiang X. Construction and expression of recombinant uricase expressing genetically engineered bacteria and its application in rat model of hyperuricemia. Int J Mol Med. 2020;45(5):1488-1500. https://doi.org/10.3892/ijmm.2020.4512.
• [134] Singh TP, Natraj BH. Next-generation probiotics: a promising approach towards designing personalized medicine. Crit Rev Microbiol. 2021;47(4):479-498. https://doi.org/10.1080/1040841x.2021.1902940.
• [135] Al-Fakhrany OM, Elekhnawy E. Next-generation probiotics: the upcoming biotherapeutics. Mol Biol Rep. 2024;51(1):505. https://doi.org/10.1007/s11033-024-09398-5.
• [136] Ceccarelli G, Borrazzo C, Pinacchio C, Santinelli L, Innocenti GP, Cavallari EN, Celani L, Marazzato M, Alessandri F, Ruberto F, Pugliese F, Venditti M, Mastroianni CM, d'Ettorre G. Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study. Front Nutr. 2021;7:613928. https://doi.org/10.3389/fnut.2020.613928.